Statutory Professor of Translational Medicine
- Director of the translational program of the Oxford Translational Myeloma Centre (OTMC)
Prof Anjan Thakurta's goals for the OTMC are focused on advancing personalised care and cure of Multiple Myeloma. In collaboration with NDORMS and other Oxford colleagues, he leads the adoption of molecular diagnostics and minimal residual disease (MRD) assessment plans to set up a new model of clinical care in Oxford and beyond.
He also leads a cross functional team to build a Myeloma Biobank at the Botnar Institute for Musculoskeletal Sciences and large Myeloma Datahub to assist new research and collaborations.
His personal research focus is understanding the biological drivers of molecularly defined high risk or targeted Myeloma segments and clinical resistance and role of novel therapeutics to address their clinical needs.
Outside of Oxford, Anjan is involved in the development of therapeutics in cancer and neurodegenerative disease at a small biotech in Boston, Massachusetts..
Previously Prof Thakurta worked in the pharmaceutical industry in research, development and approvals of drugs and diagnostics in hematological cancers such as Multiple Myeloma and Acute Myeloid Leukemia. He led the collaborative industry-academia Myeloma Genome Project that helped establish the comprehensive landscape of newly diagnosed and relapsed and refractory Myeloma genome. He focused on the late-stage translational, and diagnostics development and approval of multiple drugs in Myeloma and Acute Myeloid Leukemia.
Professor Thakurta obtained a MSc from Jawaharlal Nehru University, Delhi and MTech from IIT, Delhi, holds a PhD in genetics from Cambridge University and did postdoctoral research at Harvard and at the National Cancer Institute, USA. He is a fellow of Reuben college.
Anjan is a foodie and likes a certain brand of beverage of Scottish variety!